From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Both pharma giants have had difficulty producing enough of the drugs to meet demand. And though each saw their stocks soar due to GLP-1s, there is a better way to play the market. Over the past ...

If trusted partners in health, including pharmaceutical companies, can tackle the stigma of obesity and GLP-1s head-on with effective patient resources for emotional support and personalised care ...

Sanofi now has the go-ahead from the FDA to market the GLP-1 drug in the US. The drug, originally developed by Zealand Pharma, has been available for several years in Europe under the brand name ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Over the last 24 months, the growth we have seen from GLP-1s has been the focal topic for the global pharmaceutical sector and subsequent read-across has had significant traction across the wider ...